Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action.

Fujita Y, Inagaki N.

J Diabetes Investig. 2014 May 4;5(3):265-75. doi: 10.1111/jdi.12214. Epub 2014 Apr 2. Review.

PMID:
24843771
[PubMed]
Free PMC Article
2.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
[PubMed - indexed for MEDLINE]
3.

Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes.

Kim Y, Babu AR.

Diabetes Metab Syndr Obes. 2012;5:313-27. doi: 10.2147/DMSO.S22545. Epub 2012 Aug 31.

PMID:
22977310
[PubMed]
Free PMC Article
4.

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

Kurosaki E, Ogasawara H.

Pharmacol Ther. 2013 Jul;139(1):51-9. doi: 10.1016/j.pharmthera.2013.04.003. Epub 2013 Apr 4. Review.

PMID:
23563279
[PubMed - indexed for MEDLINE]
5.

Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.

Raskin P.

Diabetes Metab Res Rev. 2013 Jul;29(5):347-56. doi: 10.1002/dmrr.2403. Review.

PMID:
23463735
[PubMed - indexed for MEDLINE]
6.

Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.

Freeman JS.

Postgrad Med. 2013 May;125(3):214-26. doi: 10.3810/pgm.2013.05.2672. Review.

PMID:
23748522
[PubMed - indexed for MEDLINE]
7.

SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.

Misra M.

J Pharm Pharmacol. 2013 Mar;65(3):317-27. doi: 10.1111/j.2042-7158.2012.01574.x. Epub 2012 Aug 9. Review.

PMID:
23356840
[PubMed - indexed for MEDLINE]
8.

SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.

Jabbour SA.

Postgrad Med. 2014 Jan;126(1):111-7. doi: 10.3810/pgm.2014.01.2731. Review.

PMID:
24393758
[PubMed - indexed for MEDLINE]
9.

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.

Whaley JM, Tirmenstein M, Reilly TP, Poucher SM, Saye J, Parikh S, List JF.

Diabetes Metab Syndr Obes. 2012;5:135-48. doi: 10.2147/DMSO.S22503. Epub 2012 Jul 23.

PMID:
22923998
[PubMed]
Free PMC Article
10.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
[PubMed - indexed for MEDLINE]
11.

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.

Abdul-Ghani MA, DeFronzo RA.

Endocr Pract. 2008 Sep;14(6):782-90. Review.

PMID:
18996802
[PubMed - indexed for MEDLINE]
12.

The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus.

Vallon V.

Annu Rev Med. 2015 Jan 14;66:255-70. doi: 10.1146/annurev-med-051013-110046. Epub 2014 Oct 17.

PMID:
25341005
[PubMed - in process]
13.

The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.

Lajara R.

Expert Opin Pharmacother. 2014 Dec;15(17):2565-85. doi: 10.1517/14656566.2014.968551. Epub 2014 Oct 15.

PMID:
25316597
[PubMed - in process]
14.

Dapagliflozin: a review of its use in type 2 diabetes mellitus.

Plosker GL.

Drugs. 2012 Dec 3;72(17):2289-312. doi: 10.2165/11209910-000000000-00000. Review.

PMID:
23170914
[PubMed - indexed for MEDLINE]
15.

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition.

Poudel RR.

Indian J Endocrinol Metab. 2013 Jul;17(4):588-93. doi: 10.4103/2230-8210.113725.

PMID:
23961473
[PubMed]
Free PMC Article
16.

Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.

Shah NK, Deeb WE, Choksi R, Epstein BJ.

Pharmacotherapy. 2012 Jan;32(1):80-94. doi: 10.1002/PHAR.1010. Review.

PMID:
22392830
[PubMed - indexed for MEDLINE]
17.

SGLT2 inhibitors: molecular design and potential differences in effect.

Isaji M.

Kidney Int Suppl. 2011 Mar;(120):S14-9. doi: 10.1038/ki.2010.511. Review.

PMID:
21358697
[PubMed - indexed for MEDLINE]
Free Article
18.

Clinical implication of SGLT2 inhibitors in type 2 diabetes.

Kim GW, Chung SH.

Arch Pharm Res. 2014 Aug;37(8):957-66. doi: 10.1007/s12272-014-0419-0. Epub 2014 Jun 21.

PMID:
24950857
[PubMed - in process]
19.

From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus.

Bays H.

Curr Med Res Opin. 2009 Mar;25(3):671-81. doi: 10.1185/03007990802710422 . Review.

PMID:
19232040
[PubMed - indexed for MEDLINE]
20.

Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.

Washburn WN, Poucher SM.

Expert Opin Investig Drugs. 2013 Apr;22(4):463-86. doi: 10.1517/13543784.2013.774372. Epub 2013 Mar 1. Review.

PMID:
23452053
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk